Last reviewed · How we verify
Cefaprin (cefapirin)
At a glance
| Generic name | cefapirin |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | cefapirin |
| Target | Sigma non-opioid intracellular receptor 1 |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1974 |
Approved indications
- Bacterial endocarditis
- Bacterial infection due to Klebsiella pneumoniae
- Bacterial septicemia
- Escherichia coli urinary tract infection
- Haemophilus influenzae pneumonia
- Infection due to Escherichia coli
- Infection due to Staphylococcus aureus
- Infection of bone
- Infection of skin AND/OR subcutaneous tissue
- Infectious disorder of joint
- Klebsiella Pneumoniae Osteomyelitis
- Klebsiella cystitis
- Lower respiratory tract infection
- Osteomyelitis due to Staphylococcus aureus
- Pneumonia
- Pneumonia due to Streptococcus
- Prevention of Perioperative Infection
- Proteus Mirabilis Osteomyelitis
- Proteus urinary tract infection
- Rhinoscleroma
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cefaprin CI brief — competitive landscape report
- Cefaprin updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI